Budesonide-albuterol

Approved

EEndeavor Health

Budesonide-albuterol is one of 3 therapeutic programs targeting Eosinophilic Asthma. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Eosinophilic AsthmaNot yet recruiting

Eosinophilic AsthmaApproved

Not yet recruiting

Competition

Competitive Landscape

2 competitors in Eosinophilic Asthma

#DrugCompanyPhaseTrials

Fasenra

AstraZeneca

Approved

1 2

Budesonide-albuterol

EEndeavor Health

Approved

1 3

KT-621

KKymera Therapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

ApprovedNot yet recruiting

Eosinophilic Asthma

NCT07654842

Clinical

Trials by Indication[1]

Eosinophilic Asthma1 trial

Fasenra Demonstrates Durability Over the Full 8-week Treatment Period

Not yet recruiting·EEndeavor Health·Approved·NCT07654842·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Budesonide-albuterol. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Budesonide-albuterol. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Endeavor Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: EEndeavor Health

Budesonide-albuterol

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Eosinophilic Asthma1 trial

References

Drug Info

Quick Facts

Related News